Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).
Khoury P, Akuthota P, Ackerman SJ, Arron JR, Bochner BS, Collins MH, Kahn JE, Fulkerson PC, Gleich GJ, Gopal-Srivastava R, Jacobsen EA, Leiferman KM, Francesca LS, Mathur SK, Minnicozzi M, Prussin C, Rothenberg ME, Roufosse F, Sable K, Simon D, Simon HU, Spencer LA, Steinfeld J, Wardlaw AJ, Wechsler ME, Weller PF, Klion AD. Khoury P, et al. Among authors: kahn je. J Leukoc Biol. 2018 Jul;104(1):69-83. doi: 10.1002/JLB.5MR0118-028R. Epub 2018 Apr 19. J Leukoc Biol. 2018. PMID: 29672914 Free PMC article. Review.
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Roufosse FE, et al. Among authors: kahn je. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. doi: 10.1016/j.jaci.2012.07.055. Epub 2012 Oct 4. J Allergy Clin Immunol. 2013. PMID: 23040887 Free PMC article. Clinical Trial.
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ; HES Mepolizumab study group. Roufosse F, et al. Among authors: kahn je. J Allergy Clin Immunol. 2020 Dec;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037. Epub 2020 Sep 18. J Allergy Clin Immunol. 2020. PMID: 32956756 Free PMC article. Clinical Trial.
Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review.
Chapuis E, Bousquet E, Viallard JF, Terrier B, Amoura Z, Batani V, Brézin A, Cacoub P, Caminati M, Chazal T, Comarmond C, Durieu I, Ebbo M, Grall M, Ledoult E, Losappio L, Mattioli I, Mékinian A, Padoan R, Regola F, Schroeder J, Seluk L, Trefond L, Wechsler ME, Lefevre G, Kahn JE, Sève P, Groh M. Chapuis E, et al. Among authors: kahn je. Front Immunol. 2024 Apr 23;15:1379611. doi: 10.3389/fimmu.2024.1379611. eCollection 2024. Front Immunol. 2024. PMID: 38720897 Free PMC article. Review.
Sustained response to mepolizumab in refractory Churg-Strauss syndrome.
Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Blétry O. Kahn JE, et al. J Allergy Clin Immunol. 2010 Jan;125(1):267-70. doi: 10.1016/j.jaci.2009.10.014. J Allergy Clin Immunol. 2010. PMID: 20109753 No abstract available.
Venous thrombosis and predictors of relapse in eosinophil-related diseases.
Réau V, Vallée A, Terrier B, Plessier A, Abisror N, Ackermann F, Benainous R, Bohelay G, Chabi-Charvillat ML, Cornec D, Desbois AC, Faguer S, Freymond N, Gaillet A, Hamidou M, Killian M, Le Jeune S, Marchetti A, Meyer G, Osorio-Perez F, Panel K, Rautou PE, Rohmer J, Simon N, Tcherakian C, Vasse M, Zuelgaray E, Lefevre G, Kahn JE, Groh M. Réau V, et al. Among authors: kahn je. Sci Rep. 2021 Mar 18;11(1):6388. doi: 10.1038/s41598-021-85852-9. Sci Rep. 2021. PMID: 33737704 Free PMC article.
189 results